Leticia (Desogestrel, Ethinylestradiol)

The combination suppresses the hypothalamic‑pituitary‑ovarian axis, lowering luteinising hormone and follicle‑stimulating hormone release, which prevents ovulation. Ethinylestradiol stabilises the endometrium, while desogestrel thickens cervical mucus and alters the uterine lining, together blocking fertilisation and implantation.

The dosing regimen for Leticia is determined by the prescribing clinician. Typically, it is taken once daily at the same time for a 21‑day active phase followed by a hormone‑free interval, but the exact schedule must be individualized and confirmed by a healthcare professional.

Leticia is classified as pregnancy category X, meaning it must not be used during pregnancy because it can harm the fetus. It is also not recommended while breastfeeding, as hormonal exposure may affect milk production and infant health. Alternative methods should be considered.

To order Leticia, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Leticia contains desogestrel, a third‑generation progestin, which is associated with a lower incidence of androgenic side effects compared with earlier progestins. Its estrogen component, ethinylestradiol, is standard across most combined pills, offering comparable contraceptive efficacy while differing mainly in tolerability profiles.

Leticia tablets should be stored at ambient temperature, below 25 °C, in their original blister pack to protect from moisture and light. Keep the medication out of reach of children and do not use after the expiry date printed on the packaging.

Leticia is taken orally, usually one tablet each day at the same time. A typical cycle consists of 21 consecutive active tablets followed by a 7‑day hormone‑free interval, during which withdrawal bleeding occurs. Patients should follow the prescribing clinician’s instructions for missed doses.

Serious risks include venous thromboembolism, arterial thrombosis, hypertension, severe liver disease, and rare allergic reactions such as anaphylaxis. Women with a history of clotting disorders, smoking over age 35, or certain cardiovascular conditions should be evaluated carefully before use.

Leticia is contraindicated in women who are pregnant, have known or suspected estrogen‑dependent tumors, active liver disease, uncontrolled hypertension, a history of thromboembolic events, or who are smokers over 35 years of age. It should also be avoided in individuals with known hypersensitivity to any component of the tablet.